Clinical trial · Interventional
Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches. We propose to conduct a prospective study to evaluate early therapeutic response using 18F-FDG PET before and after the 1st cycle of neo-adjuvant chemotherapy for breast cancer patients. Variation of 18F-FDG PET uptake is compared to clinical and echographical tumor response evaluated after 3 cycles of chemotherapy. The purpose is to estimate the capacity of 18F-FDG PET to differentiate responder and non-responder patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDG-PET | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Other: FDG-PET
Primary outcomes (1)
- measure
- Variation rate of SUV(BSA max)before and after the 1st cycle of neoadjuvant chemotherapy
- timeFrame
- before and 3 weeks after 1st cycle
Secondary outcomes (1)
- measure
- Comparison to clinical and ultrasound assessment after the 3rd cycle of chemotherapy
- timeFrame
- 3 weeks after the 3rd cycle
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 * Breast cancer treated by neo-adjuvant chemotherapy (T\>2cm) * Measurable lesions ,assessed clinically and by ultrasound * Delay minimum between biopsy and PET: 15 days * PS-WHO: 0 Exclusion Criteria: * T\<2cm * Inflammatory breast cancer (T4d) * Diabetic patients unbalanced (glycemia\>1.40) * Pregnant or lactating women
References
Publications (0)
Data not yet available